Baiocchi C, Landonio G, Cacioppo C, Calgaro M, Cattaneo D, Ferrari M, Majno M
Department of Oncology, Niguarda Cà Granda Hospital, Milan, Italy.
Tumori. 1996 May-Jun;82(3):225-7.
MRCC responds poorly to usual treatments. Recently floxuridine (FUDR) has been administered by chronomodulated infusion, obtaining interesting results. In order to simplify the infusion, we used continuous non chronomodulated infusion.
We treated 17 patients affected by MRCC with continuous non chronomodulated infusion of FUDR. Toxicity was evaluated according to WHO criteria. Responses were recorded as complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).
Sixty-four courses of therapy were administered; 15/17 patients, treated with a median of 4 cycles, were evaluable for the response. Only 1 patient showed a grade 3 toxicity (mucositis and diarrhoea); 6 patients showed grade 1-2 diarrhoea; 2 grade 1-2 nausea and vomiting; 1 grade 2 anaemia and thrombocytopenia. No patient obtained CR; 2 PR (lasting 7 and 9 months respectively) and 4 SD (lasting 4,5,6 and 9 months) were observed.
In our experience continuous non chronomodulated infusion of FUDR did not show important general toxicity. The observed responses were not good enough. We think that a better selection of patients (good performance status) and the use of FUDR in an earlier stage of disease, can obtain better results.
转移性肾细胞癌（MRCC）对常规治疗反应不佳。最近，氟尿苷（FUDR）采用时辰调节输注给药，取得了有趣的结果。为了简化输注方式，我们采用了非时辰调节的持续输注。
我们对17例MRCC患者采用非时辰调节的FUDR持续输注进行治疗。根据世界卫生组织（WHO）标准评估毒性。将反应记录为完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）和疾病进展（PD）。
共进行了64个疗程的治疗；17例患者中有15例接受了中位4个周期的治疗，可评估反应。仅1例患者出现3级毒性（粘膜炎和腹泻）；6例患者出现1 - 2级腹泻；2例出现1 - 2级恶心和呕吐；1例出现2级贫血和血小板减少。无患者获得CR；观察到2例PR（分别持续7个月和9个月）和4例SD（分别持续4、5、6和9个月）。
根据我们的经验，非时辰调节的FUDR持续输注未显示出重要的全身毒性。观察到的反应不够理想。我们认为，更好地选择患者（良好的身体状况）以及在疾病早期使用FUDR，可能会取得更好的结果。
